1. Use of a fluid pharmaceutical site-specific sustained release composition in the manufacture of a medicament for the treatment of recurrent expanding hematoma or hemorrhage as a result of hemorrhagic state in the brain, wherein the pharmaceutical composition comprises: (i) a therapeutic amount of at least one hemostatic agent and (ii) a pharmaceutically acceptable a carrier, wherein the carrier comprises a plurality of microparticles, wherein the therapeutic agent is dispersed within each microparticle wherein composite itsiya formulated for administration locally into the cavity or space occupied hematoma or subdural space on the surface of the brain, iotlichayuscheesya in that the therapeutic amount is effective to reduce the expanding hematoma or recurrent bleeding in comparison with the untreated control without entering the systemic circulation in quantities causing unwanted effekty.2 side. Use according to claim 1, wherein hemorrhagic condition is the result of traumatic brain injury (TBI) .3. Use according to claim 1, characterized in that the condition is hemorrhagic bleeding after surgical evacuation gematomy.4. Use according to claim 1 wherein the condition is hemorrhagic chronic subdural hematoma (HSG) .5. Use according to claim 1 wherein the condition is hemorrhagic intracerebral hematoma (VMG) .6. Use according to claim 5, wherein a spontaneous intracerebral hematoma intracerebral hematoma (VMG) .7. Use according to claim 5, wherein intracerebral hematoma, intracerebral hematoma is traumatic (VMG) .8. Use according to claim 1, wherein hemorrhagic y
